Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 7
Submit an article Journal homepage
205
Views
0
CrossRef citations to date
0
Altmetric
Letters to Editor

Occult central nervous system involvement guides therapeutic choices in blastic plasmacytoid dendritic cell neoplasms

Elisa Buzzattia Hematology, Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy;b Fondazione Policlinico Tor Vergata, Rome, ItalyView further author information
,
Giovangiacinto Paternoa Hematology, Department of Biomedicine and Prevention, University Tor Vergata, Rome, ItalyView further author information
,
Raffaele Palmieria Hematology, Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy;b Fondazione Policlinico Tor Vergata, Rome, ItalyView further author information
,
Fabiana Espositoa Hematology, Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy;b Fondazione Policlinico Tor Vergata, Rome, ItalyView further author information
,
Maria Rosaria Pascalea Hematology, Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy;b Fondazione Policlinico Tor Vergata, Rome, ItalyView further author information
,
Flavia Mallegnia Hematology, Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy;b Fondazione Policlinico Tor Vergata, Rome, ItalyView further author information
,
Luca Guarneraa Hematology, Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy;b Fondazione Policlinico Tor Vergata, Rome, ItalyView further author information
,
Gianmario Pasqualonea Hematology, Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy;b Fondazione Policlinico Tor Vergata, Rome, ItalyView further author information
,
Maria Antonietta Irno Consalvoa Hematology, Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy;b Fondazione Policlinico Tor Vergata, Rome, ItalyView further author information
,
Daniela Frabonia Hematology, Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy;b Fondazione Policlinico Tor Vergata, Rome, ItalyView further author information
,
Federico Morettia Hematology, Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy;b Fondazione Policlinico Tor Vergata, Rome, ItalyView further author information
,
Arianna Savia Hematology, Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy;b Fondazione Policlinico Tor Vergata, Rome, ItalyView further author information
,
Beatrice Borsellinod Ancona University, Ancona, ItalyView further author information
,
Luca Maurillob Fondazione Policlinico Tor Vergata, Rome, ItalyView further author information
,
Francesco Buccisanoa Hematology, Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy;b Fondazione Policlinico Tor Vergata, Rome, ItalyView further author information
,
Giuseppe Sconocchiac Laboratory of Tumor Immunology and Immunotherapy, Institute of Translation Pharmacology, Department of Medicine, National Research Council of Italy (CNR), Rome, ItalyView further author information
,
Adriano Vendittia Hematology, Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy;b Fondazione Policlinico Tor Vergata, Rome, ItalyCorrespondence[email protected]
View further author information
&
Maria Ilaria Del Principea Hematology, Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy;b Fondazione Policlinico Tor Vergata, Rome, ItalyView further author information
 show all
Pages 1754-1757 | Received 10 Oct 2021, Accepted 01 Feb 2022, Published online: 06 Mar 2022

References

  • Quijano S, López A, Manuel Sancho J, Spanish Group for the Study of CNS Disease in NHL, et al. Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. J Clin Oncol. 2009;27(9):1462–1469.
  • Bromberg JE, Breems DA, Kraan J, et al. CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies. Neurology. 2007; 68(20):1674–1679.
  • Del Principe MI, Buzzatti E, Piciocchi A, et al. Clinical significance of occult Central nervous system disease in adult acute lymphoblastic leukemia. A multicenter report from the campus ALL network. Haematologica. 2021;106(1):39–45.
  • Julia F, Petrella T, Beylot-Barry M, et al. Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients. Br J Dermatol. 2013;169(3):579–586.
  • Pileri A, Delfino C, Grandi V, et al. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): the cutaneous sanctuary. G Ital Dermatol Venereol. 2012;147(6):603–608.
  • Pagano L, Valentini CG, Pulsoni A, GIMEMA-ALWP (Gruppo Italiano Malattie EMatologiche dell'Adulto, Acute Leukemia Working Party), et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an italian multicenter study. Haematologica. 2013;98(2):239–246.
  • Subirá D, Castañón S, Aceituno E, et al. Flow cytometric analysis of cerebrospinal fluid samples and its usefulness in routine clinical practice. Am J Clin Pathol. 2002;117(6):952–958.
  • Del Principe MI, Gatti A, Johansson U, et al. ESCCA/ISCCA protocol for the analysis of cerebrospinal fluid by multiparametric flow-cytometry in hematological malignancies. Cytometry B Clin Cytom. 2021;100(3):269–281.
  • Sconocchia G, Keyvanfar K, El Ouriaghli F, et al. Phenotype and function of a CD56+ peripheral blood monocyte. Leukemia. 2005;19(1):69–76.
  • Martín-Martín L, Almeida J, Pomares H, et al. Blastic plasmacytoid dendritic cell neoplasm frequently shows occult Central nervous system involvement at diagnosis and benefits from intrathecal therapy. Oncotarget. 2016;7(9):10174–10181.
  • Pemmaraju N, Wilson NR, Khoury JD, et al. Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm. Blood. 2021;138(15):1373–1377.
  • Jen EY, Gao X, Li L, et al. FDA approval summary: Tagraxofusp-erzs for treatment of blastic plasmacytoid dendritic cell neoplasm. Clin Cancer Res. 2020;26(3):532–536.
  • Pemmaraju N, Lane AA, Sweet KL, et al. Tagraxofusp in blastic plasmacytoid Dendritic-Cell neoplasm. N Engl J Med. 2019;380(17):1628–1637.
  • Beziat G, Ysebaert L. Tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN): a brief report on emerging data. Onco Targets Ther. 2020;13:5199–5205.
  • Greenwell IB, Davis J, Li H, et al. Outcomes of CNS involvement in blastic plasmacytoid dendritic cell neoplasm (BPDCN). J Clin Oncol. 2021;39(15_suppl):e19043–e19043.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.